Breve descripción
To evaluate the Pharmacokinetics, Pharmacodynamics, Efficacy, and Safety of Ravulizumab in Pediatric Participants (2 to < 18 Years of Age) with Primary Immunoglobulin A Nephropathy (IgAN) or Immunoglobulin A Vasculitis Associated Nephritis (IgAVN)
Médico del ensayo / Coordinador del estudio
Ana Aristiguieta
Estimated Enrollment
18
Estimated End Date
November 2027
Trial is for people with
Pediatric ages 2 to 17 years of age with IgAN or IgAVN
Study Goal
The primary objective of this study is to characterize the pharmacokinetics (PK) and pharmacodynamics (PD) of treatment with ...
What is involved for the patient?
Participation in this study might take a little more than two years and includes: • Checking if you can join: This takes about six ...
About the drug or intervention
Ravulizumab mechanism of action involves inhibition of the terminal complement pathway by targeting and binding to the C5 complement ...